MY198324A - Methods of treating or preventing cholesterol related disorders - Google Patents

Methods of treating or preventing cholesterol related disorders

Info

Publication number
MY198324A
MY198324A MYPI2018000605A MYPI2018000605A MY198324A MY 198324 A MY198324 A MY 198324A MY PI2018000605 A MYPI2018000605 A MY PI2018000605A MY PI2018000605 A MYPI2018000605 A MY PI2018000605A MY 198324 A MY198324 A MY 198324A
Authority
MY
Malaysia
Prior art keywords
methods
treating
related disorders
cholesterol related
preventing cholesterol
Prior art date
Application number
MYPI2018000605A
Other languages
English (en)
Inventor
Joyce Chi Yee Chan
John P Gibbs
Clapton S Dias
Scott Wasserman
Robert Andrew Donald Scott
Christi L Clogston
Timothy David Osslund
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46124771&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY198324(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MY198324A publication Critical patent/MY198324A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
MYPI2018000605A 2011-05-10 2012-05-10 Methods of treating or preventing cholesterol related disorders MY198324A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161484610P 2011-05-10 2011-05-10
US201161562303P 2011-11-21 2011-11-21
US201261595526P 2012-02-06 2012-02-06
US201261614417P 2012-03-22 2012-03-22
US201261642363P 2012-05-03 2012-05-03

Publications (1)

Publication Number Publication Date
MY198324A true MY198324A (en) 2023-08-24

Family

ID=46124771

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI2018000605A MY198324A (en) 2011-05-10 2012-05-10 Methods of treating or preventing cholesterol related disorders
MYPI2013004036A MY173860A (en) 2011-05-10 2012-05-10 Methods of treating or preventing cholesterol related disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI2013004036A MY173860A (en) 2011-05-10 2012-05-10 Methods of treating or preventing cholesterol related disorders

Country Status (36)

Country Link
US (2) US20130064825A1 (enExample)
EP (2) EP2707029B1 (enExample)
JP (3) JP6166717B2 (enExample)
KR (5) KR20250127346A (enExample)
CN (3) CN113786482A (enExample)
AP (1) AP2013007303A0 (enExample)
AR (1) AR086344A1 (enExample)
AU (5) AU2012253434B2 (enExample)
CA (1) CA2835294C (enExample)
CL (2) CL2013003214A1 (enExample)
CR (1) CR20130640A (enExample)
CY (1) CY1122967T1 (enExample)
DK (1) DK2707029T3 (enExample)
EA (1) EA031228B1 (enExample)
ES (1) ES2781749T3 (enExample)
HR (1) HRP20200545T1 (enExample)
HU (1) HUE049018T2 (enExample)
IL (4) IL311262B2 (enExample)
JO (2) JOP20200043A1 (enExample)
LT (1) LT2707029T (enExample)
ME (1) ME03765B (enExample)
MX (2) MX378241B (enExample)
MY (2) MY198324A (enExample)
PE (3) PE20240547A1 (enExample)
PH (2) PH12013502287A1 (enExample)
PL (1) PL2707029T3 (enExample)
PT (1) PT2707029T (enExample)
RS (1) RS60292B1 (enExample)
SG (1) SG194855A1 (enExample)
SI (1) SI2707029T1 (enExample)
SM (1) SMT202000183T1 (enExample)
TW (5) TWI610683B (enExample)
UA (2) UA114602C2 (enExample)
UY (1) UY34063A (enExample)
WO (1) WO2012154999A1 (enExample)
ZA (1) ZA201309173B (enExample)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
PE20140372A1 (es) 2011-01-28 2014-03-24 Sanofi Sa Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9
BR112014000392A2 (pt) * 2011-07-14 2017-02-21 Pfizer tratamento com anticorpos anti-pcsk9
AR087305A1 (es) * 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
CN103930444B (zh) 2011-09-16 2020-08-04 瑞泽恩制药公司 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
EA039663B1 (ru) * 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
KR20150023711A (ko) 2012-06-15 2015-03-05 제넨테크, 인크. 항-pcsk9 항체, 제제, 투여, 및 사용 방법
CN104540852B (zh) 2012-08-13 2018-10-02 瑞泽恩制药公司 具有pH-依赖性结合特性的抗-PCSK9抗体
WO2014144080A2 (en) * 2013-03-15 2014-09-18 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
GB2523527A (en) * 2013-04-05 2015-09-02 Weiming Xu Screen compounds for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9)
TWI679019B (zh) * 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
US10111953B2 (en) * 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
EP2810955A1 (en) 2013-06-07 2014-12-10 Sanofi Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
JP2016523847A (ja) 2013-06-07 2016-08-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｐｃｓｋ９のインヒビターの投与によりアテローム性動脈硬化を阻害する方法
EP2862877A1 (en) 2013-10-18 2015-04-22 Sanofi Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
CA2916259C (en) * 2013-06-28 2024-02-20 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
CN104371019B (zh) * 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
ES2779126T3 (es) * 2013-10-11 2020-08-13 Sanofi Biotechnology Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
WO2015054619A2 (en) * 2013-10-11 2015-04-16 Sanofi Use of a pcsk9 inhibitor to treat hyperlipidemia
CN118105482A (zh) * 2013-11-12 2024-05-31 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
MX2016006583A (es) * 2013-11-20 2016-09-06 Cymabay Therapeutics Inc Tratamiento de hipercolesterolemia familiar homocigotica.
EP2975058A1 (en) * 2014-07-15 2016-01-20 Kymab Limited Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
WO2015092394A1 (en) * 2013-12-17 2015-06-25 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
DE112014005747T5 (de) * 2013-12-17 2016-10-06 Kymab Limited Antikörper zur Verwendung bei der Behandlung von Zuständen, die mit spezifischen PCSK9 Varianten in spezifischen Patientenpopulationen in Beziehung stehen
TWI713444B (zh) * 2013-12-17 2020-12-21 英商凱美寶有限公司 人類標靶
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
EP2886558A1 (en) * 2013-12-17 2015-06-24 Kymab Limited Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
CA2935285A1 (en) * 2014-02-21 2015-08-27 Medimmune, Llc Anti-pcsk9-glp-1 fusions and methods for use
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
HUE066839T2 (hu) * 2014-03-17 2024-09-28 Sanofi Biotechnology Eljárások kardiovaszkuláris kockázat csökkentésére
UA120756C2 (uk) 2014-03-20 2020-02-10 Сімабей Терапьютікс, Інк. Лікування внутрішньопечінкових холестатичних захворювань
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
WO2015157697A1 (en) 2014-04-11 2015-10-15 Cymabay Therapeutics, Inc. Treatment of nafld and nash
WO2015171777A1 (en) 2014-05-07 2015-11-12 Amgen Inc. Autoinjector with shock reducing elements
AU2015271676A1 (en) 2014-06-03 2016-11-10 Amgen Inc. Devices and methods for assisting a user of a drug delivery device
AU2015274545B2 (en) 2014-06-11 2019-02-28 SpecGx LLC Oxidative dearomatization of berbines
EP3169710A1 (en) * 2014-07-14 2017-05-24 Amgen Inc. Crystalline antibody formulations
EP3929218A1 (en) * 2014-07-14 2021-12-29 Amgen, Inc Crystalline antibody formulations
EP3332790A1 (en) * 2014-07-15 2018-06-13 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
EP4328245A3 (en) * 2014-07-15 2024-06-05 Kymab Ltd. Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
JP6912374B2 (ja) * 2014-07-16 2021-08-04 サノフィ・バイオテクノロジー 高コレステロール血症を有する高心血管リスク患者を処置するための方法
WO2016011256A1 (en) 2014-07-16 2016-01-21 Sanofi Biotechnology METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (heFH)
MX392725B (es) 2014-10-14 2025-03-24 Amgen Inc Dispositivo de inyeccion de farmaco con indicadores visuales y audibles.
CA2964470A1 (en) * 2014-10-17 2016-04-21 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies
JP2017531682A (ja) 2014-10-23 2017-10-26 アムジエン・インコーポレーテツド 医薬製剤の粘度低下
EP3689394A1 (en) 2014-12-19 2020-08-05 Amgen Inc. Drug delivery device with live button or user interface field
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CA3069716C (en) 2015-02-17 2021-11-09 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
US20180066070A1 (en) * 2015-02-18 2018-03-08 Universitat Zurich Acetylated pcsk9
EP3981450A1 (en) 2015-02-27 2022-04-13 Amgen, Inc Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
EP3928763B1 (en) * 2015-03-02 2022-05-04 Medlab Clinical U.S., Inc. Transmucosal and transdermal delivery systems
US12168070B2 (en) 2015-03-02 2024-12-17 Medlab Clinical U.S., Inc. Transmucosal and transdermal delivery systems
WO2016169454A1 (zh) * 2015-04-21 2016-10-27 舒泰神（北京）生物制药股份有限公司 一种神经生长因子组合物及注射粉剂
US20170044516A1 (en) 2015-08-11 2017-02-16 Industrial Technology Research Institute Biochemistry reactive material and device for eliminating electronegative low-density lipoprotein (ldl) and method for treating blood or plasma ex vivo to eliminate electronegative low-density lipoprotein therein
WO2017031151A1 (en) 2015-08-18 2017-02-23 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
US10568882B2 (en) 2015-08-21 2020-02-25 Srx Cardio, Llc Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use
US10865185B2 (en) 2015-08-21 2020-12-15 Srx Cardio, Llc Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity
EP3337497B1 (en) 2015-08-21 2023-07-12 SRX Cardio, LLC Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
CN106810609A (zh) * 2015-11-27 2017-06-09 苏州君盟生物医药科技有限公司 抗pcsk9抗体及其应用
JP7082568B2 (ja) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド 信号伝達キャップ付き自動注射器
RU2739208C2 (ru) * 2015-12-31 2020-12-21 Цзянсу Хэнжуй Медицин Ко., Лтд. Анти-pcsk9 антитело, его антигенсвязывающий фрагмент и их медицинское применение
JP2019509714A (ja) 2016-01-05 2019-04-11 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． Ｐｃｓｋ９抗体、その抗原結合フラグメント及び医薬用途
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
US11200298B2 (en) 2016-03-15 2021-12-14 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
GB201608323D0 (en) * 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
JP7309363B2 (ja) 2016-05-13 2023-07-18 アムジエン・インコーポレーテツド バイアル・スリーブ組立体
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
WO2017200715A1 (en) * 2016-05-19 2017-11-23 Cymabay Therapeutics, Inc. Treatment of severe hyperlipidemia
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
TW201803905A (zh) 2016-06-20 2018-02-01 克馬伯有限公司 用於免疫腫瘤學之多重專一性抗體
US11285266B2 (en) 2016-07-01 2022-03-29 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
IL265692B2 (en) * 2016-09-29 2024-03-01 Amgen Inc Low-viscosity antigen binding proteins and methods of making them
EP3522918A1 (en) 2016-10-06 2019-08-14 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
EP3532127A1 (en) 2016-10-25 2019-09-04 Amgen Inc. On-body injector
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JOP20190112A1 (ar) * 2016-11-14 2019-05-14 Amgen Inc علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
CN108239150A (zh) 2016-12-24 2018-07-03 信达生物制药(苏州)有限公司 抗pcsk9抗体及其用途
JP2020503976A (ja) 2017-01-17 2020-02-06 アムジエン・インコーポレーテツド 注入デバイスならびに関連する使用および組立方法
MX2019009755A (es) 2017-02-17 2019-10-07 Amgen Inc Mecanismo de insercion para dispositivo de suministro de farmacos.
WO2018151890A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
ES3051784T3 (en) 2017-03-06 2025-12-30 Amgen Inc Drug delivery device with activation prevention feature
CA3055402A1 (en) * 2017-03-06 2018-09-13 Merck Patent Gmbh Aqueous anti-pd-l1 antibody formulation
EP3592402A1 (en) 2017-03-07 2020-01-15 Amgen Inc. Needle insertion by overpressure
IL303449B2 (en) 2017-03-09 2024-08-01 Amgen Inc Insertion mechanism for a drug delivery device
PT3600491T (pt) 2017-03-28 2023-10-18 Amgen Inc Sistema e método de haste de êmbolo e conjunto de seringa
KR102401796B1 (ko) 2017-04-13 2022-05-25 카딜라 핼쓰캐어 리미티드 신규의 펩타이드 기재 pcsk9 백신
WO2018226565A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
US11590294B2 (en) 2017-06-08 2023-02-28 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
JP7195276B2 (ja) 2017-06-22 2022-12-23 アムジエン・インコーポレーテツド デバイス起動による衝突／衝撃の低減
WO2018237225A1 (en) 2017-06-23 2018-12-27 Amgen Inc. Electronic drug delivery device comprising a cap activated by a switch assembly
AU2018291702A1 (en) * 2017-06-30 2020-02-06 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition comprising PCSK-9 antibody and use thereof
EP3651832B1 (en) 2017-07-14 2023-12-13 Amgen Inc. Needle insertion-retraction system having dual torsion spring system
JP7649105B2 (ja) 2017-07-21 2025-03-19 アムジエン・インコーポレーテツド 薬物容器のためのガス透過性シーリング部材及び組立方法
MA49676A (fr) 2017-07-25 2020-06-03 Amgen Inc Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
US11617837B2 (en) 2017-07-25 2023-04-04 Amgen Inc. Drug delivery device with gear module and related method of assembly
EP3664863A2 (en) 2017-08-09 2020-06-17 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
US11077246B2 (en) 2017-08-18 2021-08-03 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
ES2939292T3 (es) 2017-10-04 2023-04-20 Amgen Inc Adaptador de flujo para dispositivo de administración de fármacos
CN111132711B (zh) 2017-10-06 2022-07-01 安进公司 带有联锁组件的药物递送装置及相关组装方法
US11464903B2 (en) 2017-10-09 2022-10-11 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
IL273663B2 (en) 2017-11-03 2025-05-01 Amgen Inc System and methods for disinfecting a drug delivery device
WO2019090303A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Fill-finish assemblies and related methods
US20200261648A1 (en) 2017-11-06 2020-08-20 Amgen Inc. Drug delivery device with placement and flow sensing
EP3706826A1 (en) 2017-11-10 2020-09-16 Amgen Inc. Plungers for drug delivery devices
MX2020004996A (es) 2017-11-16 2020-08-27 Amgen Inc Un mecanismo de pestillo de puerta para un dispositivo de administracion de farmacos.
JP6639463B2 (ja) * 2017-12-21 2020-02-05 アムジエン・インコーポレーテツド ホモ接合性家族性高コレステロール血症の治療方法
CN110464842B (zh) * 2018-05-11 2022-10-14 信达生物制药(苏州)有限公司 包含抗pcsk9抗体的制剂及其用途
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
US20210128844A1 (en) 2018-07-24 2021-05-06 Amgen Inc. Delivery devices for administering drugs
MX2021000748A (es) 2018-07-24 2021-03-26 Amgen Inc Dispositivos de suministro para administrar farmacos.
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
MA53320A (fr) 2018-07-31 2021-11-03 Amgen Inc Ensemble de trajet de fluide pour dispositif d'administration de médicament
KR20210079275A (ko) * 2018-08-24 2021-06-29 에스페리온 테라피유틱스 인코포레이티드 고콜레스테롤 관련 병으로 치료 받고 있는 환자에서의 당뇨병의 위험 감소 방법
US20210346601A1 (en) 2018-09-24 2021-11-11 Amgen Inc. Interventional dosing systems and methods
MA53718A (fr) 2018-09-28 2022-01-05 Amgen Inc Ensemble d'activation d'échappement de fil de muscle pour un dispositif d'administration de médicament
CN117159846A (zh) 2018-10-02 2023-12-05 安进公司 具有内部力传递的用于药物递送的注射系统
TWI824026B (zh) 2018-10-05 2023-12-01 美商安進公司 具有劑量指示器之藥物遞送裝置
MA53913A (fr) 2018-10-15 2022-01-19 Amgen Inc Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament
CN117138169A (zh) 2018-10-15 2023-12-01 安进公司 药物递送装置
EP3873563A1 (en) 2018-11-01 2021-09-08 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
WO2020091956A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
CN119060040A (zh) 2019-01-18 2024-12-03 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法
US11634485B2 (en) 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
US20220160972A1 (en) 2019-04-24 2022-05-26 Amgen Inc. Syringe sterilization verification assemblies and methods
US20220273887A1 (en) 2019-08-23 2022-09-01 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
JP2023501745A (ja) * 2019-11-18 2023-01-18 エーディー ファーマシューティカルズ カンパニー，リミティド 抗ｐｃｓｋ９抗体及びその使用
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
IL307418A (en) 2021-05-21 2023-12-01 Amgen Inc A method for optimizing a filling recipe for a drug container
WO2023286766A1 (ja) * 2021-07-13 2023-01-19 浩志 貴田 抗体と遺伝子に結合能を有するポリペプチド
CN114438075A (zh) * 2022-02-25 2022-05-06 刘博巽 一种枯草芽孢杆菌前蛋白酶9靶向结合蛋白的筛选方法与应用
JP2025522576A (ja) * 2022-06-30 2025-07-15 エーディー ファーマシューティカルズ カンパニー，リミティド 抗ｐｃｓｋ９抗体製剤及びその応用
CN116983434B (zh) * 2023-09-28 2024-03-15 康霖生物科技（杭州）有限公司 用于基因治疗的核酸构建体及其用途

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3180193A (en) 1963-02-25 1965-04-27 Benedict David Machines for cutting lengths of strip material
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
JPS58166633A (ja) 1982-03-29 1983-10-01 Toshiba Corp 有機溶媒電池用正極
JPS58166634A (ja) 1982-03-29 1983-10-01 Toshiba Corp 有機溶媒電池用正極
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JPS62170639A (ja) 1986-01-22 1987-07-27 株式会社システムメンテナンス 防蟻板の取付け工法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
FR2664073A1 (fr) 1990-06-29 1992-01-03 Thomson Csf Moyens de marquage d'objets, procede de realisation et dispositif de lecture.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
EP0648265A4 (en) 1992-06-18 1996-12-04 Genpharm Int PROCESS FOR THE PRODUCTION OF NON-HUMAN TRANSGENIC ANIMALS HAVING AN ARTIFICIAL YEAST CHROMOSOME.
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
ATE352613T1 (de) 1995-08-29 2007-02-15 Kirin Brewery Chimäres tier und methode zu dessen herstellung
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
CA2407956A1 (en) 2000-05-03 2001-11-08 Amgen Inc. Modified peptides as therapeutic agents
ATE507816T1 (de) * 2001-11-14 2011-05-15 Durect Corp Injizierbare depotzusammensetzungen und deren verwendung
CN1897918A (zh) * 2003-11-17 2007-01-17 阿尔萨公司 包含两亲性分子作为混悬载体的组合物和剂型
WO2007074880A1 (ja) * 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
TW200837080A (en) * 2007-01-09 2008-09-16 Wyeth Corp Anti-IL-13 antibody formulations and uses thereof
JP5466635B2 (ja) * 2007-03-30 2014-04-09 メディミューン，エルエルシー 脱アミド化プロフィールが低減した抗体
JOP20080381B1 (ar) * 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
AU2008316587B2 (en) * 2007-10-26 2014-07-17 Merck Sharp & Dohme Corp. Anti-PCSK9 and methods for treating lipid and cholesterol disorders
AR070316A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
BRPI0919979A2 (pt) * 2008-10-29 2015-12-15 Wyeth Llc formulações de moléculas de ligação de antígeno de domínio único
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
WO2011028938A1 (en) * 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
EA031209B9 (ru) * 2010-01-15 2021-11-19 Кирин-Эмджен, Инк. Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения
WO2011109415A2 (en) * 2010-03-02 2011-09-09 Amgen Inc. Reducing viscosity of pharmaceutical formulations
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
JP6071725B2 (ja) 2013-04-23 2017-02-01 カルソニックカンセイ株式会社 電気自動車の駆動力制御装置
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
US11284893B2 (en) 2019-04-02 2022-03-29 Covidien Lp Stapling device with articulating tool assembly

Also Published As

Publication number Publication date
PH12013502287A1 (en) 2014-02-10
IL311262B2 (en) 2025-11-01
WO2012154999A1 (en) 2012-11-15
KR20210109675A (ko) 2021-09-06
JP2017160208A (ja) 2017-09-14
JO3520B1 (ar) 2020-07-05
TWI705826B (zh) 2020-10-01
KR20140031938A (ko) 2014-03-13
US20210047434A1 (en) 2021-02-18
KR20250127346A (ko) 2025-08-26
EP2707029B1 (en) 2020-01-15
PE20141159A1 (es) 2014-09-19
TW201536323A (zh) 2015-10-01
IL229276A0 (en) 2014-01-30
CL2013003214A1 (es) 2014-06-20
CN113786482A (zh) 2021-12-14
AU2017232084B2 (en) 2019-11-21
BR112013028819A2 (pt) 2017-01-31
UA114602C2 (uk) 2017-07-10
HUE049018T2 (hu) 2020-08-28
DK2707029T3 (da) 2020-03-30
JOP20200043A1 (ar) 2017-06-16
SI2707029T1 (sl) 2020-08-31
CL2017003288A1 (es) 2018-04-27
UY34063A (es) 2012-11-30
LT2707029T (lt) 2020-07-10
MX378241B (es) 2025-03-04
AU2022215259A1 (en) 2022-09-29
UA126229C2 (uk) 2022-09-07
TWI877669B (zh) 2025-03-21
RS60292B1 (sr) 2020-07-31
PE20240547A1 (es) 2024-03-19
IL288048A (en) 2022-01-01
IL281178A (en) 2021-04-29
IL288048B2 (en) 2024-09-01
TW202417041A (zh) 2024-05-01
AP2013007303A0 (en) 2013-12-31
AU2017232084A1 (en) 2017-10-12
ES2781749T3 (es) 2020-09-07
EA031228B1 (ru) 2018-12-28
TWI609695B (zh) 2018-01-01
JP6599527B2 (ja) 2019-10-30
EA201391668A1 (ru) 2014-06-30
IL311262B1 (en) 2025-07-01
JP6400768B2 (ja) 2018-10-03
EP2707029A1 (en) 2014-03-19
JP2014516953A (ja) 2014-07-17
KR102132496B1 (ko) 2020-07-09
EP3597218A1 (en) 2020-01-22
CN103841992A (zh) 2014-06-04
ZA201309173B (en) 2021-05-26
IL281178B (en) 2021-12-01
NZ717550A (en) 2021-08-27
CA2835294A1 (en) 2012-11-15
IL229276B (en) 2021-03-25
MY173860A (en) 2020-02-25
IL288048B1 (en) 2024-05-01
CY1122967T1 (el) 2021-10-29
TW202108172A (zh) 2021-03-01
TWI610683B (zh) 2018-01-11
PL2707029T3 (pl) 2020-07-27
AU2025234149A1 (en) 2025-10-09
KR20200086745A (ko) 2020-07-17
US20130064825A1 (en) 2013-03-14
ME03765B (me) 2021-04-20
SMT202000183T1 (it) 2020-05-08
MX2013013187A (es) 2014-03-21
AU2020201219A1 (en) 2020-03-12
AU2012253434B2 (en) 2017-07-06
CN103841992B (zh) 2021-08-13
TWI809272B (zh) 2023-07-21
JP2018199717A (ja) 2018-12-20
KR20230066480A (ko) 2023-05-15
CN107261139A (zh) 2017-10-20
HRP20200545T1 (hr) 2020-10-02
PE20181790A1 (es) 2018-11-15
TW201306865A (zh) 2013-02-16
PH12019501274A1 (en) 2020-09-14
SG194855A1 (en) 2013-12-30
CA2835294C (en) 2023-09-19
AU2012253434A1 (en) 2013-12-19
JP6166717B2 (ja) 2017-07-19
MX2019004264A (es) 2021-12-08
TW201811367A (zh) 2018-04-01
CR20130640A (es) 2014-01-14
KR102528752B1 (ko) 2023-05-08
AR086344A1 (es) 2013-12-04
IL311262A (en) 2024-05-01
NZ734570A (en) 2021-11-26
PT2707029T (pt) 2020-04-22
AU2020201219B2 (en) 2022-05-12
NZ618300A (en) 2016-04-29

Similar Documents

Publication Publication Date Title
PH12019501274A1 (en) Methods of treating or preventing cholesterol related disorders
TN2013000467A1 (en) Methods of treating or preventing cholesterol related disorders
MY168961A (en) Antibodies to pcsk9 and uses thereof
PH12014501261A1 (en) Pcsk9 antagonists
HK1257523A1 (zh) 用於治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物
TN2009000410A1 (en) Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
PH12015502761A1 (en) Antisense oligomers and conjugates targeting pcsk9
EP3486319A3 (en) Compositions and methods comprising serine protease variants
AU2016219704A1 (en) Anti-Notch1 antibodies
HK1255331A1 (zh) 抗pcsk9抗体及其应用
MA35807B1 (fr) Procedes de traitement ou de prevention de troubles associés au cholesterol